Interview, Podcast
a16z Podcast | Incenting Innovation Inside, Loonshots to Moonshots
- The scientific method is projected to democratize access to universal truths and revive past civilizations' insights through measurement and experimentation.
- Revolutionary innovations, particularly in biotechnology and drug discovery, are expected to originate from a vast market of small entities rather than large, established empires that tend to suppress new ideas.
- Future organizational strategy requires identifying and funding a "portfolio of loonshots"—ideas challenging existing belief systems with proof of concept—regardless of immediate market projections.
- A "moonshot" is defined as a successful destination, whereas an unsuccessful attempt remains a "loonshot," necessitating a system that tolerates failure during the transition.
- Transformative ideas often face "false fails" caused by execution flaws rather than fundamental errors, requiring internal distinction to sustain momentum.
- In drug discovery, innovation is predicted to struggle if projects cannot survive the "three deaths of the loonshot," where early stumbling makes good ideas appear stupid.
- Organizational behavior will be driven by structural incentives rather than culture, with a specific "phase transition" occurring as companies grow where the balance shifts from "stake in outcome" to "perks of rank."
- In small companies, "stake in outcome" is dominant; in large companies, "perks of rank" become primary, causing the same individuals to shift from championing to ridiculing ideas.
- Leaders can maintain "dynamic equilibrium" and prevent organizational stagnation by adjusting four control parameters: equity fraction, return on politics, project skill fit, and management span.
- The concept of a fixed "magic number" for organizational size is replaced by a range of 30 to 5,000 employees, contingent on the specific adjustment of the four control parameters.
- Successful leadership is expected to act as "gardeners" balancing "artists" and "soldiers," avoiding the "Moses" approach of anointing ideas from a central authority.
- The future of biology involves a shift from science to engineering, moving from bespoke processes to machine-automatable systems to address healthcare and environmental challenges.
- A critical future function involves evolving the "product manager" role to serve as the "concrete instantiation" of dynamic equilibrium between engineers and sales, effectively setting organizational temperature.
- Organizations will operate in two phases simultaneously (innovation and execution) only at the edge of a phase transition, allowing blocks of "ice" (rigidity) and "liquid" (fluidity) to coexist.
- Market fit is frequently "three years too early," requiring organizations to create their own markets rather than wait for existing demand.
- Project skill fit is predicted to prevent wasted time on politics, while management span should vary based on task requirements: narrow for quality-critical assembly and wide for experimental technology groups.
- The transfer of ideas from the lab to the market involves a significant jump where technologies initially "suck," requiring the creation of product and market fit simultaneously.
- Reliance on a single visionary leader is unsustainable; without structural support, organizations relying on a "Moses" figure will eventually fail due to the hysteresis effect.
- Historical precedents like the National Science Foundation and DARPA demonstrate the efficacy of creating "phase separation" within structures to mobilize innovation.
- The long-term viability of firms depends on evolving product management to connect siloed functions and maintain the dynamic equilibrium necessary for sustained innovation.